(BAX) Baxter International - Overview
Stock: IV Solutions, Infusion Devices, Generic Injectables, Surgical Sealants, Dialysis
| Risk 5d forecast | |
|---|---|
| Volatility | 57.2% |
| Relative Tail Risk | -20.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.64 |
| Alpha | -43.84 |
| Character TTM | |
|---|---|
| Beta | 0.944 |
| Beta Downside | 1.248 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.44% |
| CAGR/Max DD | -0.29 |
EPS (Earnings per Share)
Revenue
Description: BAX Baxter International January 03, 2026
Baxter International Inc. (NYSE:BAX) is a U.S.-based, diversified healthcare company that markets a broad range of products-including sterile IV solutions, infusion devices, parenteral nutrition, generic injectables, surgical hemostats, advanced operating-room equipment, smart-bed systems, patient-monitoring tools, and respiratory devices-across hospitals, dialysis centers, ambulatory surgery facilities, and home-care settings.
The firm operates through three segments: Medical Products and Therapies; Healthcare Systems and Technologies; and Pharmaceuticals. Its distribution model blends a direct sales force with independent distributors, drug wholesalers, and specialty pharmacies, and it maintains a global footprint spanning North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Key recent metrics: FY 2023 revenue reached approximately $12.5 billion, with the Medical Products and Therapies segment contributing roughly 65% of sales; operating margin hovered near 12%, reflecting steady cost-control despite inflationary pressure on raw materials. The aging U.S. population and rising chronic-disease prevalence continue to drive demand for Baxter’s infusion and renal-care solutions, while reimbursement reforms in Europe pose a modest upside-risk to margins.
For a deeper quantitative view, you might explore ValueRay’s interactive dashboard on Baxter’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -864.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: 34.70% < 20% (prev 22.02%; Δ 12.68% < -1%) |
| CFO/TA 0.04 > 3% & CFO 845.0m > Net Income -864.0m |
| Net Debt (7.51b) to EBITDA (1.14b): 6.61 < 3 |
| Current Ratio: 2.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (514.0m) vs 12m ago 0.78% < -2% |
| Gross Margin: 31.30% > 18% (prev 0.37%; Δ 3092 % > 0.5%) |
| Asset Turnover: 49.06% > 50% (prev 41.25%; Δ 7.81% > 0%) |
| Interest Coverage Ratio: 1.66 > 6 (EBITDA TTM 1.14b / Interest Expense TTM 279.0m) |
Altman Z'' 4.67
| A: 0.19 (Total Current Assets 6.87b - Total Current Liabilities 2.97b) / Total Assets 20.05b |
| B: 0.68 (Retained Earnings 13.71b / Total Assets 20.05b) |
| C: 0.02 (EBIT TTM 462.0m / Avg Total Assets 22.92b) |
| D: 0.98 (Book Value of Equity 13.71b / Total Liabilities 13.95b) |
| Altman-Z'' Score: 4.67 = AA |
Beneish M -2.92
| DSRI: 1.02 (Receivables 1.86b/1.73b, Revenue 11.24b/10.64b) |
| GMI: 1.20 (GM 31.30% / 37.46%) |
| AQI: 0.93 (AQ_t 0.50 / AQ_t-1 0.53) |
| SGI: 1.06 (Revenue 11.24b / 10.64b) |
| TATA: -0.09 (NI -864.0m - CFO 845.0m) / TA 20.05b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of BAX shares?
Over the past week, the price has changed by -5.47%, over one month by +7.02%, over three months by +16.78% and over the past year by -32.32%.
Is BAX a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.6 | 4.3% |
| Analysts Target Price | 21.6 | 4.3% |
BAX Fundamental Data Overview February 18, 2026
P/S = 0.949
P/B = 1.6612
P/EG = 36.6767
Revenue TTM = 11.24b USD
EBIT TTM = 462.0m USD
EBITDA TTM = 1.14b USD
Long Term Debt = 9.47b USD (from longTermDebt, last quarter)
Short Term Debt = 3.00m USD (from shortLongTermDebt, last quarter)
Debt = 9.70b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 7.51b USD (from netDebt column, last quarter)
Enterprise Value = 18.40b USD (10.67b + Debt 9.70b - CCE 1.97b)
Interest Coverage Ratio = 1.66 (Ebit TTM 462.0m / Interest Expense TTM 279.0m)
EV/FCF = 56.98x (Enterprise Value 18.40b / FCF TTM 323.0m)
FCF Yield = 1.76% (FCF TTM 323.0m / Enterprise Value 18.40b)
FCF Margin = 2.87% (FCF TTM 323.0m / Revenue TTM 11.24b)
Net Margin = -7.68% (Net Income TTM -864.0m / Revenue TTM 11.24b)
Gross Margin = 31.30% ((Revenue TTM 11.24b - Cost of Revenue TTM 7.72b) / Revenue TTM)
Gross Margin QoQ = 19.40% (prev 33.51%)
Tobins Q-Ratio = 0.92 (Enterprise Value 18.40b / Total Assets 20.05b)
Interest Expense / Debt = 0.60% (Interest Expense 58.0m / Debt 9.70b)
Taxrate = 21.0% (US default 21%)
NOPAT = 365.0m (EBIT 462.0m * (1 - 21.00%))
Current Ratio = 2.31 (Total Current Assets 6.87b / Total Current Liabilities 2.97b)
Debt / Equity = 1.58 (Debt 9.70b / totalStockholderEquity, last quarter 6.13b)
Debt / EBITDA = 6.61 (Net Debt 7.51b / EBITDA 1.14b)
Debt / FCF = 23.25 (Net Debt 7.51b / FCF TTM 323.0m)
Total Stockholder Equity = 6.94b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.77% (Net Income -864.0m / Total Assets 20.05b)
RoE = -12.44% (Net Income TTM -864.0m / Total Stockholder Equity 6.94b)
RoCE = 2.81% (EBIT 462.0m / Capital Employed (Equity 6.94b + L.T.Debt 9.47b))
RoIC = 2.20% (NOPAT 365.0m / Invested Capital 16.58b)
WACC = 5.14% (E(10.67b)/V(20.37b) * Re(9.39%) + D(9.70b)/V(20.37b) * Rd(0.60%) * (1-Tc(0.21)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈417.4m ; Y1≈274.0m ; Y5≈125.0m
Fair Price DCF = N/A (negative equity: EV 3.98b - Net Debt 7.51b = -3.53b; debt exceeds intrinsic value)
EPS Correlation: -71.28 | EPS CAGR: -18.09% | SUE: -0.88 | # QB: 0
Revenue Correlation: -71.53 | Revenue CAGR: -5.71% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.31 | Chg30d=-0.174 | Revisions Net=-8 | Analysts=13
EPS current Year (2026-12-31): EPS=1.91 | Chg30d=-0.353 | Revisions Net=-13 | Growth EPS=-15.9% | Growth Revenue=+1.0%
EPS next Year (2027-12-31): EPS=2.08 | Chg30d=-0.382 | Revisions Net=-9 | Growth EPS=+8.8% | Growth Revenue=+2.1%